Last Updated: 08 Nov 2024
Executive Summary
Jazz Pharmaceuticals PLC (JAZZ) is a biopharmaceutical company with a strong financial performance and promising growth prospects. The company's latest stock price of $119.08 represents a potential upside of 4.5% based on the analyst target price of $174.18. With a stable financial position, positive analyst ratings, and a strong pipeline of products, JAZZ is well-positioned for continued growth in the healthcare sector.
Company Overview
Jazz Pharmaceuticals plc is a global biopharmaceutical company that focuses on developing and commercializing innovative medicines for unmet medical needs. The company has a portfolio of products that target various therapeutic areas, including oncology, neurology, and hematology/oncology. Jazz Pharmaceuticals has a global presence with operations in the United States, Europe, and internationally.
Fundamental Analysis
Revenue: JAZZ reported revenue of $3.91 billion for the trailing twelve months (TTM), representing a modest growth of 0.069% year-over-year.
Earnings: The company's diluted EPS for the TTM was $5.89, indicating a solid earnings growth of 0.643% year-over-year.
Profitability: JAZZ has a profit margin of 10.1% and an operating margin of 19.5%, demonstrating the company's ability to generate profits from its operations.
Valuation: The company's trailing PE ratio of 18.94 is slightly below the industry average, suggesting that the stock may be undervalued.
Balance Sheet: Jazz Pharmaceuticals has a strong balance sheet with $1.42 billion in EBITDA and $6.89 billion in market capitalization.
Technical Analysis
Trend: The stock price has been trending sideways in recent months, with a 50-day moving average of $110.49 and a 200-day moving average of $112.97.
Support and Resistance: The stock price has found support at $99.06 and resistance at $134.17 in the past 52 weeks.
Technical Indicators: The relative strength index (RSI) is currently at 55, indicating that the stock is neither overbought nor oversold.
Short Term Outlook
In the short term, JAZZ's stock price may continue to fluctuate within the current trading range. However, the company's strong financial performance and positive analyst ratings suggest that the stock has the potential to move higher.
Long Term Outlook
The long-term outlook for JAZZ is positive. The company has a strong pipeline of products in development, which could drive future growth. Additionally, the company's focus on unmet medical needs positions it well for continued success in the healthcare sector.
Analyst Recommendations
Analysts are generally bullish on JAZZ, with 5 strong buy ratings, 10 buy ratings, and 3 hold ratings. The average analyst target price is $174.18, suggesting a potential upside of 4.5% from the current stock price.
